Andrea Pfeifer Sells 10,000 Shares of AC Immune (NASDAQ:ACIU) Stock

AC Immune (NASDAQ:ACIU) CEO Andrea Pfeifer sold 10,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $2.79, for a total transaction of $27,900.00. Following the sale, the chief executive officer directly owned 3,820,288 shares of the company’s stock, valued at $10,658,603.52. The trade was a 0.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AC Immune Trading Down 0.7%

ACIU traded down $0.02 during trading on Monday, hitting $2.77. 224,826 shares of the stock traded hands, compared to its average volume of 313,492. The firm has a market capitalization of $281.90 million, a P/E ratio of -3.38 and a beta of 1.65. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.87 and a quick ratio of 1.02. The firm has a 50-day moving average of $2.95 and a 200 day moving average of $3.08. AC Immune has a 12-month low of $1.60 and a 12-month high of $4.00.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.01. The business had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $0.33 million. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 125.26%. Equities research analysts anticipate that AC Immune will post -0.68 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. EFG International AG bought a new position in AC Immune in the 4th quarter worth $41,000. Private Advisor Group LLC bought a new position in AC Immune in the 3rd quarter worth $48,000. Sei Investments Co. bought a new position in AC Immune in the 2nd quarter worth $51,000. Goldman Sachs Group Inc. raised its holdings in AC Immune by 46.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after purchasing an additional 5,920 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new position in AC Immune in the 3rd quarter worth $63,000. 51.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ACIU has been the subject of several analyst reports. Weiss Ratings cut shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 8th. Wall Street Zen raised shares of AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Jefferies Financial Group reissued a “buy” rating and set a $7.00 price target on shares of AC Immune in a research report on Friday, March 13th. Finally, BTIG Research reissued a “buy” rating and set a $8.00 price target on shares of AC Immune in a research report on Monday, May 4th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $7.50.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.